Introduction:
Evotec, a biotechnology company, has announced that its subsidiary, Just-Evotec Biologics, has expanded its partnership with Advanced BioScience Laboratories (ABL) to develop and manufacture antibodies against HIV. The collaboration aims to design efficient manufacturing processes and conduct clinical trials for these antibodies.
- Evotec’s subsidiary, Just-Evotec Biologics, has extended its relationship with Advanced BioScience Laboratories (ABL) to work together on developing and manufacturing antibodies against HIV.
- Under the new contract, Just-Evotec Biologics will develop a third broadly neutralizing antibody (bNAb) and perform large-scale manufacturing for this bNAb and a previously developed bNAb for a Phase I clinical study.
- The collaboration will leverage Just-Evotec Biologics’ biomanufacturing platform to provide an integrated solution for the development and manufacturing of these therapeutic options targeting HIV.
- Advanced BioScience Laboratories has a history of supporting the U.S. government’s efforts to develop prevention and therapeutic products against HIV, and this partnership strengthens their tradition.
- The expansion of this partnership highlights the ongoing efforts to combat HIV and develop new treatment options through collaborative efforts between biotechnology companies and research organizations.
Conclusion:
Evotec’s subsidiary, Just-Evotec Biologics, has expanded its partnership with Advanced BioScience Laboratories to develop and manufacture antibodies against HIV. This collaboration aims to advance the development of new treatment options for HIV through the design of efficient manufacturing processes and the conduct of clinical trials. This partnership highlights the ongoing efforts in the biopharmaceutical industry to combat HIV and develop effective prevention and therapeutic products.
